96 results about "Nucleolus" patented technology

The invention relates to the field of cell classification, in particular to a cell classification and function evaluation method and system based on nucleolus morphology. The method provided by the invention comprises the following steps: S101, acquiring microscopic image data of a biological sample; s102, acquiring a first region of interest, a second region of interest and a third region of interest; s103, extracting kernel feature data; s104, carrying out first classification on cells in the biological sample; s105, carrying out second classification on the C-type cells in the biological sample; and S106, calculating the number and / or proportion of the A-type cells and the B-type cells in the biological sample so as to evaluate the functional state of the tissues or organs corresponding to the biological sample. The method can accurately and sensitively reflect and evaluate the functional state of the tissue or organ corresponding to the biological sample, and is especially suitable for the biological sample which is lack of a specific marker and has strong heterogeneity.

The present disclosure provides compositions and methods of use thereof for targeting trans- splicing of a pre-mRNA in a cell utilizing small nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNAs), and related methods.

The invention discloses an application of a soybean nucleolus GTP binding protein gene GmNSN1 in soybean resistance to soybean mosaic virus diseases. The invention relates to an application of a soybean nucleolus GTP binding protein gene GmNSN1 as shown in SEQ ID NO.1 and SEQ ID NO.2 in genetic engineering modification of soybean mosaic virus resistance. The soybean nucleolus GTP binding protein gene GmNSN1 can negatively regulate and control the resistance of soybeans to diseased soybean mosaic virus diseases, and the antiviral response of the soybeans can be activated due to function deficiency of the soybean nucleolus GTP binding protein gene GmNSN1. The gene is knocked out through a CRISPR / Cas9 gene editing technology, so that the resistance of soybeans to the soybean mosaic virus disease can be remarkably improved.

The invention belongs to the technical field of plant gene engineering, and particularly relates to an OsNUC1 gene and application of a gene mutant constructed by the OsNUC1 gene to regulation and control of rice plant height, leaf length and panicle type. The regulation is to regulate the plant height and leaf growth of the rice and influence the shape of the ear part. Compared with the prior art, the OsNUC1 gene mutant has the following advantages: (1) the OsNUC1 is directionally edited by utilizing a CRISPR / Cas9 gene editing technology, an OsNUC1 gene mutant rice material is obtained, the biological phenotype of the OsNUC1 gene mutant rice material is investigated, the phenotype investigation on T1-generation seedlings of the OsNUC1 shows that the plant heights and the leaf lengths of one-week-old and two-week-old seedlings of the mutant are obviously higher than those of wild seedlings, the leaf widths have no obvious difference, and the OsNUC1 gene mutant rice material has a good application prospect; the result shows that the OsNUC1 can regulate the plant height and the leaf growth of the rice and influence the shape of the ear part. (2) it is proved that the nucleolin gene OsNUC1 is negatively regulated by a transcription factor OsARF7, and the phenotypes such as the plant height, the leaf length, the grain length and the grain width of the OsNUC1 / OsARF7 mutant are more obvious than those of the OsNUC1 mutant. The invention further proves the application of the OsNUC1 gene in regulation and control of rice plant height and leaf growth.

Provided herein is an antibody having specificity for nucleophosprotein 1 (NPM1), which is capable of binding to nucleophosprotein 1 located on the surface of a cell; and antibody-drug conjugates (ADCs) comprising such antibodies are provided. Also provided herein are methods of treating a cancer in which NPM1 is expressed on the surface of a cancer cell by administering to a subject an NPM1-binding antibody or antibody conjugate as described herein and a chemotherapeutic drug.

The invention discloses a corn kernel development regulation gene ZmRH51 as well as an encoding protein, a functional marker and an application of the corn kernel development regulation gene ZmRH51. According to the application, a corn kernel mutant m223 is taken as a basic material, heterozygote of the corn kernel mutant m223 is hybridized with Zheng 58 (Z58) to construct an F2 segregation population, then phenotype identification and cytological observation are performed on the segregation population of the offspring, the gene ZmRH51 for controlling the mutation phenotype of the m223 is obtained through genetic analysis, BSR-seq analysis and map-based cloning, the gene is positioned in a nucleolus region, and the mutation phenotype of the m223 is controlled. The ZmRH51 is used for coding RNA helicase of a DEAD-Box gene family, and research shows that ZmRH51 participates in ribosome assembly and can influence processing of pre-rRNA in corn kernels; the excellent allelic variation genotype of the excavated ZmRH51 gene in the aspect of grain thickness is obtained through further excavation, the grain thickness and hundred-grain weight of the ZmRH51 gene can be increased through the utilization of the gene, and then the yield is increased. In addition, distribution and utilization potentials of different haplotypes in a selfing line are researched, and technical support and excellent germplasm resources are provided for utilization of the gene.

The present invention discloses a fluorescent probe, comprising a carbon dot surface functionalised with glucosamine. The present invention also provides a method of fabricating a fluorescent probe and a method of staining a nucleolus of a cell by contacting the fluorescent probe as disclosed herein with the cell.

The invention discloses application of a fluorescent probe in simultaneous imaging of lysosome and nucleolus and nucleic acid detection, and belongs to the technical field of fluorescent probes. The invention discloses (E)-2-(4-(ethylamino)-2-hydroxyvinyl)-3-(2-ethoxyl) benzothiazole-3-iodised salt as a fluorescent probe capable of imaging lysosome and nucleolus at the same time, and as a fluorescent probe for detecting nucleic acid. The probe provided by the invention is a red fluorescent probe, which is helpful for imaging microstructures of cells and tissues. The lysosome and the nucleolus are closely related to diagnosis of various diseases (cancers and the like) and drug research and development. Therefore, the fluorescent compound provided by the invention can provide a more accurate and effective tool for research and application in the fields of chemical industry, biological medicine and the like.

The invention discloses a preparation method and application of programmable DNA hydrogel for inhibiting breast cancer tumor activity. The DNA hydrogel is composed of an RCA long chain AL containing a multivalent AS411 aptamer sequence and an RCA long chain CL hybridized with a cholesterol single chain ss-chol. Through reasonable DNA programming sequence design, a three-dimensional DNA structure can be formed on the surface of the cell. The DNA hydrogel specifically targets cancer cells with high expression of nucleolin receptors through the synergistic effect of multivalent AS1411 and chol, and is weak in targeting to normal cells with low expression of nucleolin, so that toxic and side effects on the normal cells are effectively avoided. The DNA hydrogel has excellent programmability, hydrogel with high, medium and low pore densities can be simply prepared through flexible DNA sequence design, and the breast cancer resistance activity of the DNA hydrogel is in positive correlation with the pore density of the DNA hydrogel. In animal in-vivo experiments, the DNA hydrogel under three-dimensional and high pore density significantly inhibits breast cancer activity, and a new strategy is provided for tumor treatment.

Disclosed in the present invention are a BRIX1 inhibitor and use thereof in resisting tumors. Specifically, disclosed in the present invention is that nucleolin BRIX1 is a key regulator of the homeostasis between ribosome biogenesis and p53 activation. The research results of the present invention show that the inhibition of BRIX1 can induce nucleolar stress, leading to activation of p53, thereby inhibiting tumor growth. In addition, the present invention constructs an engineered exosome whose surface is decorated with iRGD and which is loaded with BRIX1-specific siRNA and used for cancer therapy.

The application discloses a pyridine cation mitochondrial fluorescent probe, the chemical name of the probe is 4-(8-dimethylamino-5-benzocoumarin)-methylpyridine iodine salt, and the chemical structural formula is shown as formula (I). The application further discloses application of the fluorescent probe in labeling or imaging display of mitochondrial distribution or morphology in living cells and in long-range tracking display of mitochondria in living cells and imaging display of nucleoli in cells. Experiments prove that the labeled mitochondrial fluorescent probe has high light bleaching resistance and a high fluorescence quantum yield, can realize long-range tracking of mitochondria in living cells, and can label fixed nucleoli in cells. It is indicated that the fluorescent probe has potential application and development value in the fields of fluorescent probes and tissue imaging, and has a wide application prospect.

The application provides application of nucleolin as a drug target in preparation of a double-targeted treatment drug for colorectal cancer, and application of nucleolin as a double-targeted drug target in preparation of a drug for double-targeted killing of colorectal cancer tumor cells and tumor-related fibroblasts, the drug for double-targeted killing of colorectal cancer tumor cells and tumor-related fibroblasts, a pharmaceutical composition containing the drug and application thereof. The application uses nucleolin as a common drug target of colorectal cancer tumor cells and tumor-related fibroblasts, applies a double-targeted killing drug with nucleolin as a target, simultaneously kills colorectal cancer tumor cells and tumor-related fibroblasts, removes tumor cells while destroying tumor-related fibroblast-mediated tumor supporting microenvironment, and synergistically enhances the overall treatment effect of colorectal cancer.

The present invention relates to a novel peptide that specifically binds to nucleolin, and more specifically, to a peptide expressed by a specific amino acid sequence, a conjugate comprising the peptide and an anticancer drug, a fusion peptide comprising the peptide and a cell-penetrating peptide, a composition comprising the peptide for diagnosing cancer, and a composition comprising the peptide or the conjugate for preventing or treating cancer. In the present invention, the peptide ligand AGM peptide and its mutants, screened using the MAP synthesis method and the OBOC combination method, have been shown to specifically bind to cancer cells, and their conjugates with anticancer drugs inhibit cancer growth (in vitro and in vivo). Therefore, the AGM peptide targeting nucleolin can be effectively used for diagnosis and targeted drug delivery in cancer treatment.

The application belongs to the technical field of molecular detection, and particularly relates to a method for detecting NCL conformation and G4 complex thereof based on a solid nanopore. The method is as follows: a solid nanopore is used, bias is applied on both sides of the nanopore, translocation signals of a sample to be tested through the nanopore are tested under the condition of the applied bias, and nucleolin in the sample to be tested is qualitatively and / or quantitatively analyzed through the translocation signals. By analyzing the blocking current amplitude and translocation time of NCL and G4 complex thereof entering the nanopore channel under bias, information such as the size and electrification of NCL and G4 complex thereof can be obtained. The application can detect NCL of different concentrations, greatly reduce the test cost, and at the same time, trace detection of NCL can be realized with high sensitivity and rapidness. The application provides a new research idea for targeted treatment of diseases such as cancer through detection of NCL and NCL-G4 complex.

The invention discloses an RNA (Ribonucleic Acid) fluorescent probe as well as a preparation method and application thereof in cell nucleolus staining, and belongs to the technical field of biomedical detection. The probe is a water-soluble pyridine salt compound, the chemical name of the probe is 1-(2-(2-(2, 2-dicyanovinyl))-5-(dimethylamino phenoxy) ethyl) pyridine-1-ammonium bromide, and the preparation method of the probe is characterized in that 2-(2-bromoethoxy)-4-(dimethylamino) benzaldehyde and malononitrile are used as raw materials, and the probe is synthesized through two-step reaction. The probe has the characteristics of large Stokes shift, low cytotoxicity and fluorescence enhancement after being combined with RNA (Ribonucleic Acid). Experiments prove that the probe can specifically carry out efficient fluorescence labeling on nucleolus and cytoplasm RNA in fixed cells, and a high-contrast imaging effect is obtained. The probe disclosed by the invention is simple and convenient to synthesize and excellent in performance, and has important application value in the fields of cell nucleolus research, tumor diagnosis and the like.

Provided in the present invention are a cytopathological staining kit and a staining method. The staining kit comprises a basic fuchsin staining reagent, a silver nitrate staining reagent, an ethanol-hydrochloric acid fixation solution, a gelatin-formic acid reducing solution, and a washing solution. The kit can reveal the complete cellular structure and morphology thereof, and can particularly delineate the morphology of a nucleolus of a cell nucleus.

Provided herein are antibodies specific for nucleophosmin 1 (NPM1), which are capable of binding to nucleophosmin 1 located on the surface of cells, as well as antibody-drug conjugates (ADCs) comprising such antibodies. Also provided herein are methods of treating cancers in which NPM1 is expressed on the surface of cancer cells, by administering to a subject an NPM1-binding antibody or antibody conjugate described herein and a chemotherapeutic drug.

This invention application discloses a gene regulating maize kernel development. ZmRH51 This application focuses on the encoded proteins, functional markers, and applications of maize kernel mutants. m223 Using this as the basic material, its heterozygotes were crossed with Zheng 58 (Z58) to construct the F2 segregating population. Phenotypic identification and cytological observation were performed on the progeny segregating population. Controlling populations were obtained through genetic analysis, BSR-seq analysis, and map-based cloning. m223 Genes with mutant phenotypes ZmRH51 This gene is located in the nucleolar region and encodes an RNA helicase belonging to the DEAD-Box gene family. Studies have shown that... ZmRH51 It participates in ribosome assembly and can influence the processing of pre-rRNA in maize kernels; and further mining yields... ZmRH51 The superior allelic variant genotype of this gene in terms of grain thickness can be utilized to improve grain thickness and 100-grain weight, thereby increasing yield. Furthermore, the distribution and utilization potential of different haplotypes in inbred lines were studied, providing technical support and excellent germplasm resources for the utilization of this gene.

The invention discloses an application of a fluorescent probe in preparation of a reagent for simultaneously imaging mitochondria and nucleolus. The fluorescent probe is (E)-1-methyl-4-(2-(1-methyl-1H-pyrrole-2) vinyl) pyridine-1-iodised salt. In addition, the probe and a mitochondrial red probe can be used for mitochondrial positioning at the same time. Mitochondria and nucleolus are closely related to diagnosis of various diseases (cancers and the like) and drug research and development. Therefore, the fluorescent compound provided by the invention can provide a more accurate and effective tool for research and application in the fields of chemical industry, biological medicine and the like.

The present invention belongs to the field of protein targeted degradation chimera preparation and biomedicine technology, and specifically relates to a conditional protein targeted degradation chimera based on nucleic acid aptamers, and its preparation method and application. The present invention uses nucleic acid aptamers that specifically target nucleolin as ligands to develop a series of chimera degraders for nucleolin. Further, by introducing a photosensitive nucleic acid aptamer complementary chain, a chimera that conditionally degrades nucleolin is developed, thereby achieving spatiotemporal controllable degradation of nucleolin. The protein targeted degradation chimera prepared by the present invention has good degradation efficiency and anti-tumor cell effect; at the same time, the use of nucleotides as connecting molecules greatly simplifies the difficulty of synthesizing E3 ligands; in addition, regulating the chimera activity by regulating the conformation of nucleic acid aptamers provides a new method for specifically degrading pathogenic proteins in diseased tissues, greatly reducing the toxic and side effects of chimeras on normal tissues, and has good practical application value.

The application discloses a novel radionuclide therapeutic drug targeting nucleolus DDX24 helicase and a preparation method and application thereof. 64 The Cu-DOTA-TDP-2 has good tumor targeting uptake specificity, and is expected to provide a precise molecular imaging method for esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has high radiochemical yield and specific activity, good chemical stability, high affinity for DDX24 helicase, and a simple and easy-to-operate preparation method, and can be used for the treatment of DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has excellent biological safety performance and good tumor inhibition effect in esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors.

The present invention discloses a series of novel redox-responsive nucleolin aptamer-paclitaxel conjugates as shown in formula I, a preparation method thereof and an application thereof: #imgabs0#R is -(CH2) m1 S(CH2) n1 ‑,‑(CH2) m2 SS(CH2) n2 ‑、‑(CH2) m3 SC(CH3)2S(CH2) n3 ‑, m1, n1, m2, n2, m3, n3 are 0 or positive integers. The conjugate is designed to respond to the redox heterogeneity of triple-negative breast cancer, has good water solubility and tumor specificity, and exhibits redox dual responsiveness, rapid release of PTX, and the highest anti-triple-negative breast cancer ability.

The invention discloses a preparation method of red fluorescent carbon dots with lysosome and nucleolus dual-targeting capability in the technical field of nano material synthesis and biological imaging analysis. According to the preparation method, o-phenylenediamine is taken as a carbon source, methanol is taken as a solvent in the presence of rare earth ions, and the red fluorescent carbon dots can be obtained through a solvothermal method reaction in a reaction kettle. The synthesis process is simple, the raw materials are cheap and easy to repeat, and the absolute quantum yield of the purified red fluorescent carbon dots is 11.45%, so that the luminous efficiency is high, and the technical problem that the absolute quantum yield of the red fluorescent carbon dots in the existing bioimaging field is low is solved. The prepared red fluorescent carbon dots have non-exciting light dependence, and the emission wavelength can be extended to 800 nm; the size is small, the particle size distribution is 2.5-5.5 nm, and the average particle size is about 3.75 nm; the oil-water partition coefficient (Log P value) is 0.3-0.4, the water solubility is good, the lysosome and nucleolus targeting specificity is achieved, the photobleaching resistance is high, the biocompatibility is good, and the cytotoxicity is low.

The compounds are used for the detection and imaging of amyloid plaques or both of proteins or peptides, for screening or testing the efficacy of inhibitors against amyloidosis and / or fibrillary growth of proteins or peptides, and / or for the detection of RNA and nucleolar imaging. The compounds are d 8 or d 10 Metal complexes or salts thereof. The metal complexes of said compounds can bind to amyloid proteins or peptides, plaques or both and / or RNA, nucleoli or both. This binding induces the accumulation and supramolecular self-assembly of the metal complexes, thereby causing changes in the photophysical properties of the metal complexes.

The present invention discloses the application of nucleolin in blocking porcine reproductive and respiratory syndrome virus infection, and belongs to the field of biotechnology. The present invention discovers a new PRRSV cell target protein - Nucleolin protein (NCL), and the specific siRNA for NCL and the single-stranded oligonucleotide AS1411 with specific affinity for NCL can significantly inhibit PRRSV infection, and the combined application of the two can significantly improve the ability to resist PRRSV infection. The specific siRNA of NCL and AS1411 can be developed into drugs for preventing and treating PRRSV infection, thereby providing a new idea for PRRSV research and prevention, expanding the scope of research, and having extremely important significance for actual production.

The present invention relates to the use of small artificial RNA (hereafter referred to as "smartRNA") containing sequences creating secondary structure motifs similar to C / D box small nucleolar RNAs (snoRNAs), and antisense guide sequences, as a tool for targeted upregulation of protein expression. The smartRNAs assembles into a ribonucleoprotein (RNP) complex resulting in a smartRNP, increasing the 2´-O-methylation level of one or more adenosines of the polyA-tail of the target mRNA, thereby delaying deadenylation of the targeted mRNA, resulting in increased protein production.

The invention discloses an application of a substance for reducing the activity and / or expression quantity of RPL22 protein in delaying senescence. Experiments prove that the senescence phenotype of cells can be delayed by deletion of the RPL22 protein, the senescence phenotype of the cells can be accelerated by overexpression of the RPL22 protein, in addition, in the senescence occurrence process or under the condition of overexpression of the RPL22 protein, the senescence phenotype of the cells can be accelerated by inducing reduction of the levels of HP1gamma, KAP1 and H3K9me3 heterochromatin proteins on a heterochromatin region on nucleolus rDNA, so that the senescence phenotype of the cells can be delayed, and the senescence phenotype of the cells can be accelerated. Then heterochromatin is induced to be depolymerized, the transcription level of rDNA is increased, rRNA expression is increased, and the nucleolus structure is affected. The deficiency of RPL22 can relieve the occurrence of the phenotypes. Therefore, the RPL22 can be used as a potential target for preventing, relieving or treating aging or aging-related diseases. The method has an important application value.

The present invention is directed to styryl quinolinium compounds, a process for their synthesis and their use for selective nucleoli staining in cells, preferably in living cells and for imaging rRNA.

The present invention relates to an antiviral use of a novel peptide binding specifically to nucleolin and, more specifically, to: an antiviral composition comprising a peptide represented by a specific amino acid sequence; an antiviral composition comprising a fusion peptide in which the peptide and a cell-penetrating peptide are coupled to each other; a composition comprising the aforementioned compositions for preventing or treating a viral infection; and a health functional food composition for prevention or alleviation of a viral infection. In the present invention, a AGM peptide ligand and mutants thereof were found to inhibit viral proliferation and replication (in vitro and in vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.

To provide a method and a device of evaluating and sorting a nucleolus of an embryo based on morphology in a season specific manner.SOLUTION: An evaluating and sorting method of an embryo has: a step of determining whether or not at least 2 blastomeres of 4 cells (blastomeres) are blastomeres SN (single nucleolus) having a single large nucleolus or blastomeres MN (multi-nucleoli) having a plurality of small nucleoli, in an embryo of 4-cell stage of an animal other than human; and a step of sorting an embryo in which at least two or more blastomeres are SN out of the 4 blastomeres.SELECTED DRAWING: None